Royalty Report: Drugs, Diagnostic, Disease – Collection: 3020


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Diagnostic
  • Disease
  • Diagnostic Substances
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3020

License Grant
The Licensee had purchased a License from the principal patent holder, the Licensor, to whom royalty payments were due for strip-based rapid tests sold.
License Property
Products covered by the License included those related to HIV, H.pylori, Tuberculosis and Hepatitis A.  Immunochromatography, the principle upon which the Licensee's rapid tests are based, is a technology covered by many patents.
Field of Use
The rights granted apply to the healthcare industry relating to infectious diseases.

IPSCIO Record ID: 26919

License Grant
The Company has taken a license to two U.S. patents, which expire in the financial years 2004 and 2014 respectively, covering the format of Uni-Gold(TM) rapid test device i.e. the visual result given by its one step strip test.
License Property
The Company 's Uni-Gold one step assays detect antibodies to various infectious diseases and conditions in serum and plasma or whole blood based on the principle of an immuno-chromatographic assay.  The Company currently markets four products based on this technology, Uni-Gold HIV, Uni-Gold Hepatitis B, Uni-Gold hCG (pregnancy) and Uni-Gold H. pylori.

IPSCIO Record ID: 2180

License Grant
The Company, through its subsidiary, entered into an exclusive contract to license its tuberculosis diagnostics test (rapid diagnostic test for the detection of tuberculosis).
License Property
The test utilizes a combination of three highly specialized Mycobacterium tuberculosis antigens that react with serum from persons having active TB, in just three minutes.  This ability of the test to distinguish TB infection from active disease makes it ideal for helping medical professionals select the appropriate therapy.  The indications for the use of the test for tuberculosis are living in or travel from most third world countries, and certain developed countries, a known exposure to the disease and high risk physical conditions.
Field of Use
The rights granted apply to the medical field.

IPSCIO Record ID: 4046

License Grant
The Company signed an Agreement with the Brazilian Licensee for the transfer of technology for patents applied in Brazil or other Mercosur countries for the term of the patents and the transfer of all technical information related to DPP® HIV 1/2 rapid test and the process to obtain rapid test for the detection of HIV1/2 by the DPP® technology.
License Property
This Agreement contemplates the scientific and technological co-operation between the Company and the Licensee for such activities so that the Licensee will be able to manufacture the DPP® technology in Brazil.  Under the Agreement, after the Product registration by Brazil’s National Health Surveillance Agency, the Company will supply product and the Licensee will do their best efforts to purchase each year for a period of three years from the Company the amount of 833,333 units of product at a product transfer price of $3.00 per unit for a minimum aggregate purchase obligation equal to $7.5M.  Following the purchase of $7.5 million, during each of the succeeding two years, Licensee will purchase test components as specified by Licensee at an aggregate purchase price of $1.25 million in each of the fourth and fifth year.
Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.